Decrypting neuro-cancer crosstalk in pediatric cancers of the peripheral nervous system
This project aims to explore the interactions between neurobiology and neuroblastoma to identify therapeutic targets and define subtypes benefiting from neuro-related treatments.
Projectdetails
Introduction
Cancer neuroscience has emerged as a major axis of cancer biology, at the crossroad of two biological areas. Multi-layered dialogs between cancer and nervous contingents have started to be unravelled, with pivotal roles of the nervous system in tumor initiation, growth, and invasion, in turn amplified by cancer-induced hijacking of nervous functions.
Brain Tumors and Neural Networks
Specifically, brain tumors were shown to be integrated in bona fide neuron-to-cancer synaptic networks but also to capture neural-activity dependent released factors that boost their tumor properties. In the last years, this completely rewired the view of high-grade gliomas, especially those arising in the pediatric population, suggesting specific vulnerabilities when neural networks are being shaped.
Neuro-Cancer Crosstalk in the PNS
The knowledge regarding neuro-cancer crosstalk in the peripheral nervous system (PNS) is far more fragmented and is even obscure in malignancies arising within peripheral nervous tissues. Neuroblastoma (NB) is an emblematic, deadly, pediatric cancer of the PNS, with primary tumors that develop in sympathetic ganglia or in the adrenal gland.
Impact of Neural Activity on NB
Despite its occurrence in sites of active central-to-PNS synaptic contacts, whether neural activity impacts on NB tumor features and metastatic progression is fully unknown.
Proposed Model and Objectives
We have conceived a model of NB that reproduces the embryonic and nervous microenvironment in which it arises but also the sequence of its metastatic progression. Guided by preliminary data, the objective of the proposal is to decrypt the panel of neuro-cancer functional interplays in NB, at the anatomical, electrophysiological, and molecular level.
Methodology and Aims
We will deploy multidisciplinary and cutting-edge approaches to provide a comprehensive and dynamic picture of neuro-NB dialogs, in relevant models for this pediatric cancer. Our underlying aims are to:
- Identify novel entry points for therapeutic strategies.
- Define subtypes of NB that would benefit from neuro-related therapies.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.836.141 |
Totale projectbegroting | € 1.836.141 |
Tijdlijn
Startdatum | 1-2-2024 |
Einddatum | 31-1-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Decoding and Targeting Treatment-Resistant Metastatic NeuroblastomaThis project aims to develop advanced models to study treatment resistance in neuroblastoma, identify novel therapeutic targets, and validate combination therapies for relapsed cases. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Precision Lethality to overcome clonal heterogeneity in high-risk neuroblastomaThis project aims to develop precision lethality methodologies using cell barcoding to identify effective drug combinations for treating neuroblastoma, overcoming clonal heterogeneity. | ERC Starting... | € 1.497.981 | 2024 | Details |
Automated canceR-on-A-CHip orgaN-specific metastatIc spreaDThe ARACHNID project aims to develop a multiplexed, automated tumor-metastasis-on-a-chip platform to enhance understanding and treatment of cancer metastasis, starting with pediatric tumors. | ERC Proof of... | € 150.000 | 2024 | Details |
Deciphering non-genetic determinants and targetability of cancer cell plasticity.This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment. | ERC Consolid... | € 2.000.000 | 2025 | Details |
Multimodal “4D”-therapy of pediatric high grade gliomaThis project aims to develop a novel multimodal treatment strategy for pediatric high-grade glioma by combining targeted therapies, gene therapy, and CAR-T cells to improve patient outcomes. | ERC Starting... | € 1.493.711 | 2024 | Details |
Decoding and Targeting Treatment-Resistant Metastatic Neuroblastoma
This project aims to develop advanced models to study treatment resistance in neuroblastoma, identify novel therapeutic targets, and validate combination therapies for relapsed cases.
Precision Lethality to overcome clonal heterogeneity in high-risk neuroblastoma
This project aims to develop precision lethality methodologies using cell barcoding to identify effective drug combinations for treating neuroblastoma, overcoming clonal heterogeneity.
Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD
The ARACHNID project aims to develop a multiplexed, automated tumor-metastasis-on-a-chip platform to enhance understanding and treatment of cancer metastasis, starting with pediatric tumors.
Deciphering non-genetic determinants and targetability of cancer cell plasticity.
This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.
Multimodal “4D”-therapy of pediatric high grade glioma
This project aims to develop a novel multimodal treatment strategy for pediatric high-grade glioma by combining targeted therapies, gene therapy, and CAR-T cells to improve patient outcomes.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.